Psychosocial Treatments for Bipolar Depression

A 1-Year Randomized Trial From the Systematic Treatment Enhancement Program

David J. Miklowitz, PhD; Michael W. Otto, PhD; Ellen Frank, PhD; Noreen A. Reilly-Harrington, PhD; Stephen R. Wisniewski, PhD; Jane N. Kogan, PhD; Andrew A. Niemierko, MD; Joseph R. Calabrese, MD; Lauren B. Marangell, MD; Laszlo Gyulai, MD; Mako Araga, MS; Jodi M. Gonzalez, PhD; Edwin R. Shirley, PhD; Michael E. Thase, MD; Gary S. Sachs, MD

Context: Psychosocial interventions have been shown to enhance pharmacotherapy outcomes in bipolar disorder.

Objective: To examine the benefits of 4 disorder-specific psychotherapies in conjunction with pharmacotherapy on time to recovery and the likelihood of remaining well after an episode of bipolar depression.

Design: Randomized controlled trial.

Setting: Fifteen clinics affiliated with the Systematic Treatment Enhancement Program for Bipolar Disorder.

Patients: A total of 293 referred outpatients with bipolar I or II disorder and depression treated with protocol pharmacotherapy were randomly assigned to intensive psychotherapy (n=163) or collaborative care (n=130), a brief psychoeducational intervention.

Interventions: Intensive psychotherapy was given weekly and biweekly for up to 30 sessions in 9 months according to protocols for family-focused therapy, interpersonal and social rhythm therapy, and cognitive behavior therapy. Collaborative care consisted of 3 sessions in 6 weeks.

Main Outcome Measures: Outcome assessments were performed by psychiatrists at each pharmacotherapy visit.

Results: All analyses were by intention to treat. Rates of attrition did not differ across the intensive psychotherapy (35.6%) and collaborative care (30.8%) conditions. Patients receiving intensive psychotherapy had significantly higher year-end recovery rates (64.4% vs 51.5%) and shorter times to recovery than patients in collaborative care (hazard ratio, 1.47; 95% confidence interval, 1.08-2.00; P=.01). Patients in intensive psychotherapy were 1.58 times (95% confidence interval, 1.17-2.13) more likely to be clinically well during any study month than those in collaborative care (P=.003). No statistically significant differences were observed in the outcomes of the 3 intensive psychotherapies.

Conclusions: Intensive psychosocial treatment as an adjunct to pharmacotherapy was more beneficial than brief treatment in enhancing stabilization from bipolar depression. Future studies should compare the cost-effectiveness of models of psychotherapy for bipolar disorder.

Trial Registration: clinicaltrials.gov Identifier: NCT00012558

Arch Gen Psychiatry. 2007;64:419-427

Primary outcomes included time to recovery and the proportion of patients classified as well during each of 12 study months.

Bipolar disorder is an extremely debilitating illness, in large part because of the difficulty in treating bipolar depressive episodes. Patients experience significantly greater impairment and longer times to recovery from depressive than manic episodes and high levels of residual depressive symptoms between episodes. The limited efficacy of pharmacotherapy alone has motivated the study of adjunctive psychosocial interventions. Randomized controlled trials support the efficacy of adjunctive cognitive behavior therapy (CBT), family-focused treatment (FFT) or similar forms of family psychoeduction, interpersonal and social rhythm therapy (IPSRT), and group psychoeducation in preventing depressive and manic recurrences, stabilizing symptoms, or enhancing functioning in 1- to 2-year periods. One multicenter effectiveness trial found no main effect of CBT on time to recurrence, although post hoc analyses revealed benefits in patients with fewer than 12 episodes.

Despite these important advances, it is unclear whether psychosocial treatments are effective for the acute treatment of depressed bipolar patients in routine practice settings. Family and interpersonal interventions have typically been initiated during or shortly after an acute manic,
mixed, or depressive episode to prevent further recurrences, whereas CBT and group psychoeducation have generally commenced after lengthy periods of remission. Moreover, most studies have been single-site investigations of single treatments compared with routine care conducted in the academic center where the treatment was developed.

We examined the effectiveness of adjunctive intensive psychosocial interventions in the context of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), a National Institute of Mental Health–sponsored study of the effectiveness of treatments for bipolar disorder. Across 15 study sites we randomly assigned patients to receive intensive psychosocial treatment (up to 30 sessions of CBT, IPSRT, or FFT in 9 months) or a minimal psychosocial intervention, collaborative care (CC), consisting of 3 sessions in 6 weeks. All 4 psychosocial treatments included psychoeducation, relapse prevention planning, and illness management interventions. Collaborative care was designed to provide a brief version of the most common psychosocial strategies shown to offer benefit for bipolar disorder. In contrast, the intensive treatments represented enhanced versions of these core psychoeducational interventions combined with additional treatment targets: disturbances in family relationships and communication in FFT, cognitive distortions and activity and skill deficits in CBT, and disturbances in interpersonal relationships and social rhythms in IPSRT. Consistent with the STEP-BD objective of evaluating interventions in routine practice, therapists were given modest levels of training (a weekend workshop and low-intensity ongoing monitoring) appropriate for a large-scale practical clinical trial.

We hypothesized that compared with adjunctive CC, adjunctive intensive psychosocial intervention would hasten time to recovery from bipolar depression and increase the likelihood of remaining well for 12 months. Secondly, we explored whether the 3 intensive interventions (FFT, IPSRT, and CBT) differed in their impact on depressive symptoms.

## METHODS

### PARTICIPANTS

Participants (N=293) were enrolled in STEP-BD and provided additional separate informed consent to participate in this study. All consents were approved by the respective site’s human research committee and the STEP-BD Data Safety Monitoring Board. Initially eligibility was limited to participants who had entered a 26-week double-blind placebo-controlled comparison of a mood stabilizer (defined in the “Pharmacotherapy” section) plus placebo or a mood stabilizer plus a standard antidepressant agent (bupropion or paroxetine) and were also willing to accept randomization to psychosocial treatment (randomized acute depression [RAD] study; n=236). When it became apparent that these requirements excluded many otherwise appropriate candidates for psychosocial intervention, we initiated the psychosexual acute depression (PAD) study (n=57), which included patients who were ineligible for the pharmacotherapy trial by reason of previous poor response to both of the study antidepressant agents.

### INCLUSION AND EXCLUSION CRITERIA

Participants in the RAD and PAD psychosocial studies met the following eligibility criteria: 18 years or older; meets the DSM-IV criteria for current bipolar I or II disorder and a current major depressive episode but does not meet the criteria for a DSM-IV mixed episode or depression not otherwise specified; currently being treated with a mood stabilizer or willing to initiate such treatment; not currently undergoing psychotherapy, or, if so, willing to discontinue nontreatment psychotherapy or taper sessions to 1 or fewer per month; speaks English; and willing and able to give informed consent. Patients were excluded only if they required immediate treatment for a current DSM-IV substance or alcohol abuse or dependence disorder (excluding nicotine); were pregnant or planning pregnancy in the next year; had a history of intolerance, nonresponse, or medical contraindication to paroxetine or bupropion; or required initiation of or dose changes in antipsychotic medications.

### DIAGNOSTIC EVALUATION

At the patient’s initial evaluation for STEP-BD, certified study psychiatrists administered the Affective Disorders Evaluation, a semistructured interview adapted from the *Structured Clinical Interview for DSM-IV, Patient Version*. A second certified clinical interviewer (psychiatrist, psychologist, social worker, or psychiatric nurse) independently interviewed patients using the Mini-International Neuropsychiatric Interview (version 5.0). Study diagnoses were based on a consensus between the 2 interviews.

### RANDOMIZATION TO TREATMENTS

Eligible participants were randomly assigned to intensive psychosocial treatment (FFT, CBT, or IPSRT) or to the CC control condition. Block randomization included site, bipolar I or II status, and, if also participating in the RAD study, pharmacologic treatment assignment (mood stabilizer with or without a standard antidepressant). All the sites offered CC and 2 of the 3 intensive psychotherapies. Each site chose 1 intensive psychotherapy based on its clinical expertise; the other psychotherapy was assigned randomly. Of the 15 sites, 10 offered CBT, 9 offered FFT, and 11 offered IPSRT. At the sites offering FFT, randomization was stratified further by whether family members (typically spouses, parents, or siblings) were willing to participate in family treatment. Patients without available family members could be assigned only to IPSRT, CBT, or CC.

In each stratum, 60% of the eligible patients were randomly assigned to intensive psychotherapy and 40% to CC, resulting in 163 patients being assigned to intensive psychotherapy and 130 to CC (Figure 1). Because only 159 (54.3%) of the 293 patients had family availability, the number randomly assigned to FFT (n=26) was lower than the number assigned to IPSRT (n=62) or CBT (n=75).

### PHARMACOTHERAPY

The 236 patients in the RAD study were randomly assigned to double-blind pharmacotherapy with mood stabilizers (lithium, valproate, and carbamazepine) plus placebo or plus adjunctive antidepressants. The protocol was amended in 2004 to define a mood stabilizer as any Food and Drug Administration–approved antimanic agent. The 57 patients in the PAD trial received treatment in accordance with physician-patient agreement and the STEP-BD guidelines for best-practice evidence-based pharmacotherapy.
PSYCHOSOCIAL TREATMENTS

Collaborative Care

This control intervention consisted of three 50-minute individual sessions conducted in the 6 weeks after randomization. Participants received a psychoeducational videotape and a workbook that included information about (1) the diagnosis, management, and treatment of bipolar illness; (2) the importance of medication adherence; (3) schedule management (including daily mood charting); (4) typical biases in thinking relevant to mood states; (5) improving relationships through communication skills; and (6) developing a treatment contract geared toward preventing episodes. The CC sessions focused on review of these materials and developing a treatment contract.

Cognitive Behavior Therapy

All intensive treatments consisted of up to thirty 50-minute sessions conducted in 9 months. Individual CBT sessions consisted of (1) psychoeducation regarding the course of bipolar disorder, medication adherence, and stress management; (2) life events scheduling for alleviating inactivity or reducing overstimulation; (3) cognitive restructuring; (4) problem-solving training; (5) strategies for early detection of and intervention for mood episodes; and (6) selected interventions for comorbidities, if relevant.30 Early sessions focused on monitoring activity and challenging negative thoughts; later sessions focused on challenging dysfunctional beliefs.

Interpersonal and Social Rhythm Therapy

In early sessions of IPSRT, therapists conducted an illness history with a focus on mood episodes associated with disruptions to social routines and sleep/wake cycles (social rhythms).31 A primary problem area was then chosen (ie, grief, role disputes, role transitions, or interpersonal deficits). Therapists acquainted patients with the Social Rhythm Metric,32 a self-report instrument for recording the timing of daily activities (including arising and going to bed), moods, and levels of social stimulation. As treatment progressed, therapists encouraged patients to keep stable social rhythms (eg, when to sleep, exercise, and eat), anticipate events that could disrupt rhythms, and develop plans for continued mood and social rhythm stability. Later in treatment, patients and therapists worked toward interpersonal problem resolution and rehearsed strategies for preventing similar interpersonal problems or social rhythm disruptions in the future.

Family-Focused Therapy

Family-focused therapy began with psychoeducational sessions focused on the symptoms, cause, life course, treatment, and self-management of bipolar disorder.33 Patients and relatives were encouraged to (1) develop a common understanding of precipitants of the index depressive episode, the patient’s vulnerability to future episodes, the need for continuous pharmacotherapy, and the role of stress in provoking episodes and (2) develop a relapse prevention plan involving early intervention for prodromal signs of mania or depression (eg, arranging a pharmacologic reevaluation or de-escalating stressful verbal exchanges). In the intermediate treatment phase, patients and family members participated in communication enhancement exercises designed to reduce levels of negative expressed emotion and rehearse adaptive communication skills.34 In the final phase, families identified, defined, and attempted to solve problems related to the illness (eg, methods to enhance drug adherence) or the home environment.

Figure 1. Consort diagram. CBT indicates cognitive behavior therapy; CC, collaborative care; FFT, family-focused therapy; IPSRT, interpersonal and social rhythm therapy; PAD, psychosocial acute depression study; RAD, randomized acute depression study; and STEP-BD, Systematic Treatment Enhancement Program for Bipolar Disorder.
RESULTS

STUDY SAMPLE

The 293 participants (mean ± SD age, 40.1 ± 11.8 years; range, 17-65 years; 120 males [41.0%] and 173 females [59.0%]) (Table 1) were a subset of the 423 patients who were randomly assigned to experimental treatments for acute depression in the 15 STEP-BD sites (Figure 1). Of 366 patients randomly assigned to pharmacotherapy in the RAD study, 236 (64.5%) agreed to randomization to psychosocial interventions as well. Patients who agreed to psychosocial randomization did not differ significantly from those who refused (n=130) in age, sex, education, self-identified race/ethnicity, bipolar I or II status, number of previous episodes, or age at onset.

Baseline medication data were available for 263 (89.8%) of the 293 patients. Of these, 244 (82.8%) began the psychosocial study taking 1 or more mood stabilizers, and 19 (7.2%) were not taking any mood stabilizers; 79 (30.0%) were taking atypical antipsychotics, 85 (32.3%) were taking antidepressants, and 56 (21.3%) were taking anxiolytics. There were no differences between the RAD psychosocial (n=236), RAD pharmacotherapy-only (n=130), and PAD (n=57) study subsamples on demographic or illness variables except that patients in the PAD trial were less likely to be of minority origin (P= .03) and pharmacotherapy-only patients were more likely to have an income less than $29,999 (P= .005).

BASELINE COMPARISONS OF TREATMENT GROUPS

Table 2 lists the psychosocial treatment assignments as a function of study site. The intensive psychotherapy and CC groups did not differ significantly at the time of psychosocial randomization on demographic, diagnostic, illness history, or current clinical state variables. The 2 groups also did not differ significantly in the proportion of patients being treated at the time of randomization with lithium, divalproex sodium, carbamazepine, lamotrigine, atypical antipsychotics, or any other atypical agent, adjunctive antidepressants, or anxiolytics.
Patients in the intensive group began psychosocial sessions a mean ± SD of 17.9 ± 16.1 days after randomization, and those in the CC group began 17.0 ± 10.9 days after randomization (P = .48). Patients in CC attended a mean ± SD of 2.2 ± 1.3 of 3 protocol-specified sessions (median, 3.0; range, 0-5; 4 patients received extra sessions for emergencies), whereas patients in the intensive psychotherapy group received a mean ± SD of 14.3 ± 11.4 of 30 protocol-specified sessions (median, 13.0; range, 0-30). The mean ± SD number of months of intensive psychosocial treatment was 6.8 ± 3.8. Patients in the CBT group attended a mean ± SD of 13.3 ± 11.3 sessions (median, 11.0) in a mean ± SD of 6.5 ± 4.0 months; in the IPSRT group, 16.7 ± 11.2 sessions (median, 18.5) in 7.2 ± 3.7 months; and in the FFT group, 11.5 ± 11.4 sessions (median, 11.5) in 6.5 ± 2.9 months. Neither the number of sessions (P = .09) nor the months in treatment (P = .53) differed across the intensive groups.

Of the 293 patients, 195 (66.6%) finished the full year of follow-up. Patients in the CC group were as likely to complete the study year (90/130; 69.2%) as patients in the intensive psychotherapy group (105/163; 64.4%) and did not differ in time to study dropout (log-rank $\chi^2 = 0.86; P = .35$). Likewise, there were no differences among any of the 3 intensive psychotherapies in time to dropout (log-rank $\chi^2 = 3.28; P = .07$). One-year rates of study completion were as follows: FFT, 19/26 (73%); IPSRT, 42/62 (67.7%); CBT, 44/75 (58.7%); and CC, 90/130 (69.2%).

Patients received a mean ± SD of 22.6 ± 14.0 sessions of pharmacotherapy from STEP-BD psychiatrists during the study year. The mean ± SD frequency of these sessions did not differ between the intensive psychotherapy (22.7 ± 13.5) and CC (22.5 ± 14.6) groups or across the CBT, FFT, IPSRT, or CC groups (P > .10 for all).

### RECOVERY AS A FUNCTION OF TREATMENT GROUP

Of 293 patients, 172 (58.7%) recovered from their depressive episode by the end of the study year, whereas 121 (41.3%) did not recover (n = 60) or terminated before a determination of recovery was possible (n = 61). The median ± SD time to recovery among the participants who recovered was 122 ± 79 days.

Survival analysis using the Kaplan-Meier method revealed that the cumulative proportion of recovered patients in the intensive psychotherapy conditions was higher than in the CC condition (1-year recovery rate: intensive psychotherapy group, 105/163 [64.4%]; CC group, 67/130 [51.5%]; log-rank $\chi^2 = 6.20; HR = 1.47, 99% CI, 1.08-2.00; P = .01$) ([Figure 2](#)). Median ± SD time to recovery among patients who recovered was 113 ± 78.2 days in the intensive psychotherapy group and 146 ± 80.0 days in the CC group. The proportionality of risk assumption for the survival curves was upheld ($\chi^2 = 0.17; P = .68$).

Including study site, assignment to the RAD or PAD study, family availability, and bipolar I or II status as covariates in a Cox proportional hazards model did not alter the main effect of psychosocial intervention on time to recovery (HR, 1.53; log-rank $\chi^2 = 6.93; P = .009$). Across treatment conditions, RAD trial participants recovered faster than PAD study participants (HR, 1.59; log-rank $\chi^2 = 4.55; P = .03$), and patients with family members (n = 159) (Figure 1) recovered more rapidly than those without family members (n = 134) (HR, 1.38; log-rank $\chi^2 = 3.96; P = .047$). There were no independent effects of site or bipolar I or II status or interactions of treatment group with these variables on time to recovery (P > .10 for all).

### Table 1. Demographic and Illness Characteristics of 293 Bipolar Depressed Patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean ± SD, y</td>
<td>40.13 ± 11.77</td>
</tr>
<tr>
<td>Female sex</td>
<td>173 (59)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>11 (4)</td>
</tr>
<tr>
<td>Native American</td>
<td>1 (0)</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Other</td>
<td>3 (1)</td>
</tr>
<tr>
<td>Hispanic ethnicity</td>
<td>10 (4)</td>
</tr>
<tr>
<td>Education &gt;1 y of college</td>
<td>145 (52)</td>
</tr>
<tr>
<td>Income &lt;$29,999</td>
<td>111 (43)</td>
</tr>
<tr>
<td>Marital status</td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>91 (33)</td>
</tr>
<tr>
<td>Unmarried</td>
<td>104 (37)</td>
</tr>
<tr>
<td>Separated</td>
<td>85 (31)</td>
</tr>
<tr>
<td>Other</td>
<td>159 (54)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
</tr>
<tr>
<td>Bipolar I</td>
<td>197 (67)</td>
</tr>
<tr>
<td>Bipolar II</td>
<td>90 (31)</td>
</tr>
<tr>
<td>Bipolar NOS</td>
<td>5 (2)</td>
</tr>
<tr>
<td>&gt;10 Previous manic episodes</td>
<td>192 (66)</td>
</tr>
<tr>
<td>&gt;10 Previous depressive episodes</td>
<td>196 (69)</td>
</tr>
<tr>
<td>Age at illness onset, mean ± SD, y</td>
<td>16.24 ± 8.44</td>
</tr>
<tr>
<td>Baseline MADRS score, mean ± SD†</td>
<td>21.88 ± 10.13</td>
</tr>
<tr>
<td>Baseline YMRS score, mean ± SD†</td>
<td>5.66 ± 5.70</td>
</tr>
<tr>
<td>Depression summary score, mean ± SD‡</td>
<td>7.70 ± 2.12</td>
</tr>
<tr>
<td>Mania summary score, mean ± SD‡</td>
<td>1.17 ± 1.01</td>
</tr>
<tr>
<td>Baseline global assessment of functioning, mean ± SD</td>
<td>53.06 ± 7.87</td>
</tr>
<tr>
<td>Duration of index MDE, mean ± SD, d</td>
<td>206.16 ± 755.46</td>
</tr>
<tr>
<td>Rapid cycling in previous year</td>
<td>79 (29)</td>
</tr>
<tr>
<td>Medications</td>
<td></td>
</tr>
<tr>
<td>Mood stabilizers</td>
<td>244 (93)</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>85 (32)</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>17 (6)</td>
</tr>
<tr>
<td>Lithium</td>
<td>120 (46)</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>70 (27)</td>
</tr>
<tr>
<td>Divalproex sodium</td>
<td>105 (40)</td>
</tr>
<tr>
<td>Atypical antipsychotics</td>
<td>79 (30)</td>
</tr>
<tr>
<td>Olanzapine-quetiapine</td>
<td>50 (19)</td>
</tr>
<tr>
<td>Anxiolytics</td>
<td>56 (21)</td>
</tr>
</tbody>
</table>

Abbreviations: MADRS, Montgomery-Asberg Depression Rating Scale; MDE, major depressive episode; NOS, not otherwise specified; YMRS, Young Mania Rating Scale.

*Baseline medication regimens were unavailable on 30 patients. Data are presented as number (percentage) unless otherwise indicated. Percentages are not always based on 293 patients owing to missing data.
†Refers to scores collected at intake into the study.
‡Refers to summary scores from the Clinical Monitoring Form recorded within 1 week of the date of randomization to treatment.

Downloaded From: by a Non-Human Traffic (NHT) User on 11/13/2018
RECOVERY AS A FUNCTION OF TYPE OF INTENSIVE PSYCHOTHERAPY

There was a main effect of type of intensive treatment (FFT, CBT, or IPSRT) on time to recovery (log-rank $\chi^2=8.02; P=.046$) (Figure 3). Within the 1-year timeframe, 76.9% (20/26) of the patients in the FFT group recovered (HR relative to CC, 1.87), 64.5% (40/62) of the IPSRT patients recovered (HR, 1.48), and 60.0% (45/75) of the CBT patients recovered (HR, 0.98; median±SD days, 106±70.5), and 51.5% (67/130) of the CC patients recovered. The median±SD time to recovery among patients who recovered was 103±94.1 days for FFT, 127.5±76.8 days for IPSRT, 112±72.9 days for CBT, and 146±80.0 days for CC. Results remained significant when site, RAD or PAD study status, and bipolar I or II status were included in the regression model, intensive psychosocial treatment remained associated with a greater likelihood of being well (F1,270=8.80; P=.003; adjusted odds ratio, 1.59; 95% CI, 1.17-2.13) in the intensive psychotherapy group than in the CC group (F1,281=9.13; P=.003) (Figure 4). Independent of treatment assignment, patients were more likely to be well in later study months than in earlier months (F1,281=15.65; P<.001). When site, RAD or PAD trial assignment, family availability, and bipolar I or II status were included in the regression model, intensive psychosocial treatment remained associated with a greater likelihood of being well (F1,270=8.80; P=.003; adjusted odds ratio, 1.59; 95% CI, 1.17-2.13), and there were no independent effects of the covariates (P>.10 for all).

When the intensive psychotherapy group was stratified according to form of psychotherapy, a main effect of treatment modality was observed on the proportion well (F1,281=3.02; P=.03). Almost identical main effects relative to CC were observed for FFT (odds ratio, 1.60; SE=0.27; 95% CI, 1.17-2.13), IPSRT (odds ratio, 1.61; SE=0.20; 95% CI, 1.09-2.37), and CBT (odds ratio, 1.55; SE=0.19; 95% CI, 1.07-2.25). The main effect of treatment modality was unchanged after adjusting for the effects of site, RAD or PAD study, family availability, and bipolar I or II status (F1,268=3.33; P=.02).

Table 2. Psychosocial Treatment Assignments as a Function of Study Site

<table>
<thead>
<tr>
<th>Site</th>
<th>Psychosocial Treatment Assignment, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baylor College of Medicine, Houston, Tex</td>
<td>CC 21 (16) CBT 0 FFT 4 (15) IPSRT 17 (27) Total 42</td>
</tr>
<tr>
<td>State University of New York at Buffalo</td>
<td>CC 2 (2) CBT 0 FFT 0 IPSRT 1 (2) Total 3</td>
</tr>
<tr>
<td>School of Medicine and Biomedical Sciences*</td>
<td></td>
</tr>
<tr>
<td>Case Western Reserve University School of</td>
<td>CC 16 (12) CBT 11 (15) FFT 0 IPSRT 10 (16) Total 37</td>
</tr>
<tr>
<td>Medicine, Cleveland, Ohio</td>
<td></td>
</tr>
<tr>
<td>University of Colorado Health Sciences</td>
<td>CC 8 (6) CBT 9 (12) FFT 0 IPSRT 0 Total 17</td>
</tr>
<tr>
<td>Center, Denver</td>
<td></td>
</tr>
<tr>
<td>Cornell University, Weill Medical College,</td>
<td>CC 1 (&lt;1) CBT 1 (&lt;1) FFT 0 IPSRT 0 Total 2</td>
</tr>
<tr>
<td>New York, NY*</td>
<td></td>
</tr>
<tr>
<td>University of Massachusetts Medical</td>
<td>CC 8 (6) CBT 0 (0) FFT 2 (8) IPSRT 5 (8) Total 15</td>
</tr>
<tr>
<td>School, Worcester</td>
<td></td>
</tr>
<tr>
<td>Massachusetts General Hospital, Boston</td>
<td>CC 30 (23) CBT 28 (37) FFT 12 (46) IPSRT 46 Total 70</td>
</tr>
<tr>
<td>University of Missouri School of Medicine,</td>
<td>CC 7 (5) CBT 5 (7) FFT 2 (8) IPSRT 0 Total 14</td>
</tr>
<tr>
<td>Kansas City*</td>
<td></td>
</tr>
<tr>
<td>New York University School of Medicine,</td>
<td>CC 1 (&lt;1) CBT 0 (0) FFT 0 IPSRT 0 Total 1</td>
</tr>
<tr>
<td>New York, NY*</td>
<td></td>
</tr>
<tr>
<td>University of Oklahoma Health Sciences</td>
<td>CC 5 (4) CBT 5 (7) FFT 0 IPSRT 3 (6) Total 13</td>
</tr>
<tr>
<td>Center, Tulsa</td>
<td></td>
</tr>
<tr>
<td>University of Pennsylvania School of</td>
<td>CC 9 (7) CBT 7 (9) FFT 0 IPSRT 7 (11) Total 23</td>
</tr>
<tr>
<td>Medicine, Philadelphia</td>
<td></td>
</tr>
<tr>
<td>University of Pittsburgh School of Medicine,</td>
<td>CC 10 (8) CBT 0 (0) FFT 4 (15) IPSRT 14 (23) Total 28</td>
</tr>
<tr>
<td>Medicine, Pittsburgh, Pa</td>
<td></td>
</tr>
<tr>
<td>University of Texas Health Science</td>
<td>CC 6 (5) CBT 3 (4) FFT 0 IPSRT 4 (6) Total 13</td>
</tr>
<tr>
<td>Center, San Antonio</td>
<td></td>
</tr>
<tr>
<td>University of California, San Diego, School of Medicine, La Jolla*</td>
<td>CC 0 (0) CBT 0 (0) FFT 1 (2) IPSRT 1 Total 1</td>
</tr>
<tr>
<td>Stanford University School of Medicine,</td>
<td>CC 6 (5) CBT 6 (8) FFT 2 (8) IPSRT 0 Total 14</td>
</tr>
<tr>
<td>Stanford, Calif</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>CC 130 CBT 75 FFT 26 IPSRT 62 Total 293</td>
</tr>
</tbody>
</table>

Abbreviations: CBT, cognitive behavior therapy; CC, collaborative care; FFT, family-focused therapy; IPSRT, interpersonal and social rhythm therapy.

*The site was discontinued from the Systematic Treatment Enhancement Program for Bipolar Disorder.

PROPORTION CLASSIFIED AS WELL DURING EACH TREATMENT INTERVAL

An ordinal logistic mixed-effects regression model revealed that in any given study month, the odds of a patient being well were 1.58 times greater (SE=0.15; 95% CI, 1.17-2.13) in the intensive psychotherapy group than in the CC group (F1,283=9.13; P=.003) (Figure 4). In dependent of treatment assignment, patients were more likely to be well in later study months than in earlier months (F1,283=15.65; P<.001). When site, RAD or PAD trial assignment, family availability, and bipolar I or II status were included in the regression model, intensive psychosocial treatment remained associated with a greater likelihood of being well (F1,270=8.80; P=.003; adjusted odds ratio, 1.59; 95% CI, 1.17-2.13), and there were no independent effects of the covariates (P>.10 for all).

When the intensive psychotherapy group was stratified according to form of psychotherapy, a main effect of treatment modality was observed on the proportion well (F1,281=3.02; P=.03). Almost identical main effects relative to CC were observed for FFT (odds ratio, 1.60; SE=0.27; 95% CI, 1.17-2.13), IPSRT (odds ratio, 1.61; SE=0.20; 95% CI, 1.09-2.37), and CBT (odds ratio, 1.55; SE=0.19; 95% CI, 1.07-2.25). The main effect of treatment modality was unchanged after adjusting for the effects of site, RAD or PAD study, family availability, and bipolar I or II status (F1,268=3.33; P=.02).

COMMENT

This large multisite randomized trial of bipolar patients treated with mood stabilizers compared 3 types of psychotherapy—CBT, FFT, and IPSRT—with a brief psychosocial treatment in hastening recovery from a depressive episode and maximizing the probability of remaining well during a 1-year period. In contrast to previous trials, patients entered the study early in the development of a major depressive episode (mean Montgomery-Asberg Depression Rating Scale score, 21.9) and, thus, may be more representative of the population of bipolar patients seen for acute care in clinical practice.
Given the increasing acceptance of adjunctive psychosocial interventions for bipolar disorder,\textsuperscript{13,23} we developed a 3-session comparison condition composed of the many common elements found in existing empirically supported treatments rather than choosing a medication-only control. We found that substituting any 1 of the 3 intensive, specialized, manual-driven interventions for this minimal treatment resulted in clinically significant improvements in time to recovery. Overall, patients were 1.58 times more likely to be well in any study month if they received intensive psychotherapy than if they received CC in addition to their pharmacotherapy.

The present results are consistent with those of previous efficacy trials\textsuperscript{13,15,19,20,23,24} that found that adjunctive psychotherapy delays recurrences in patients with bipolar disorder. Most of these were single-site randomized controlled trials that required therapists to undergo lengthy periods of training and certification and used time-consuming methods of fidelity monitoring. The benefits observed in the present study were achieved across sites with relatively minimal training and low-intensity supervision. Given the limited benefits of antidepressant medications in patients with bipolar depression who are taking mood stabilizers\textsuperscript{45} (see also G.S.S., A.A.N., J.R.C., et al, unpublished data, 2007), referral for intensive psychosocial treatment seems to be an especially important addition to clinical care.

In secondary analyses we found no differences among the 3 intensive psychosocial treatments in their capacity to aid and sustain recovery. However, the study was underpowered to detect small effect size differences between each of the intensive modalities. With the observed sample size of 293, a type I error rate of 0.05, a Bonferroni adjustment for 3 comparisons, and 80% power, the intensive modalities would have had to differ from each other by an HR of 3.23 to obtain a statistically reliable treatment effect. Moreover, the sample size needed to identify a statistically significant difference between each of the intensive psychosocial treatments and CC, based on the smallest observed effect size of 1.34 (CBT vs CC) would be 445 per group. Focused studies of much larger samples are needed to explore whether the potentially meaningful numerical differences observed between the groups are replicable.

The lack of statistically significant differences between the intensive modalities may also reflect the effect of shared components of the treatments, which are in many ways more striking than their differences.\textsuperscript{23,46,47} Possibly, future studies will combine the most effective components of the modalities and evaluate hybrid models of psychotherapy.\textsuperscript{48}

Patients in the intensive therapies attended fewer than half (mean, 14.3) of the 30 scheduled sessions. This rate is similar to the frequency that bipolar patients typically obtain in randomized trials (mean, 14 sessions), even when study protocols dictate greater frequencies.\textsuperscript{22,49} Without an attention control, we cannot determine whether these results are attributable to the specific focus of the intensive psychotherapy sessions or simply the greater number of therapist-patient contacts and, by extension, more opportunities to recognize clinical exacerbations and institute res-
cue strategies. However, there was no main effect of number of sessions and no interactions between treatment modality and number of sessions on time to recovery. Furthermore, a naturalistic study of psychotherapy use in the first 1000 patients to enter the STEP-BD indicated that additional sessions of nonspecialized psychotherapy do not necessarily improve outcome.

Consistent with the evidence-based treatment recommendations of the STEP-BD, approximately 80% of the participants received pharmacologic care concordant with national guidelines (E. Dennehry, PhD, written communication, May 9, 2006); however, the STEP-BD guidelines allowed considerable latitude in drug and dosage selection. The intensive psychotherapy and CC groups were balanced at the time of randomization on the proportion of patients taking each type of mood stabilizer, atypical antipsychotic, or adjunctive agent. Furthermore, the 26-week STEP-BD pharmacotherapy study revealed no differences in time to recovery among patients taking mood stabilizers with or without antidepressants (see G.S.S., A.A.N., J.R.C., et al, unpublished data, 2007). Nonetheless, differences between the intensive and nonintensive psychotherapy conditions in drug choice or dosages might have emerged during the 1-year follow-up. Masking psychiatrists to psychosocial treatment assignments might minimize this source of bias in future studies.

Most of the patients were under the care of a psychiatrist and were receiving mood stabilizers at the time of randomization, and a subset (n = 236) were willing and eligible to accept randomized treatment without a standard antidepressant agent. Although few participants were treatment naive and nearly 70% had a history of more than 10 episodes, it is possible that by pairing the entry criteria for a controlled pharmacotherapy study with a psychosocial intervention study we excluded patients who were highly treatment refractory. Consistent with this possibility, patients who participated in the RAD study had better outcomes than those who did not.

Finally, future trials need to examine the cost-effectiveness of psychosocial interventions. Intensive treatments such as IPSRT, FFT, and CBT, although seeming to be more effective than brief treatments in hastening recovery from episodes, maintaining stability, and delaying recurrences, are also more costly. Treatment-associated costs must be carefully balanced against the potential gains for patients in functioning and quality of life and, possibly, reductions in rates of hospitalization or polypharmacy.

Submitted for Publication: May 23, 2006; final revision received July 19, 2006; accepted August 4, 2006.

Author Affiliations: Departments of Psychology and Psychiatry, University of Colorado, Boulder (Dr Miklowitz); Department of Psychology, Boston University, Boston, Mass (Dr Otto); Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pa (Drs Frank and Thase); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Drs Reilly-Harrington, Nierenberg, and Sachs); Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh (Dr Wisniewski and Ms Araga); Department of Psychiatry, University of Pittsburgh School of Medicine and Community Care Behavioral Health Organization (Dr Kogan); Department of Psychiatry, Case Western Reserve University School of Medicine/University Hospitals of Cleveland, Cleveland, Ohio (Drs Calabrese and Shirley); Menninger Department of Psychiatry, Baylor College of Medicine, and VISN 16 Mental Illness Research, Education, and Clinical Center, Department of Veterans Affairs, Houston, Tex (Dr Marangell); Department of Psychiatry, University of Pennsylvania, Philadelphia (Dr Gyulai); and Department of Psychiatry, University of Texas Health Science Center, San Antonio (Dr Gonzalez).

Correspondence: David J. Miklowitz, PhD, Department of Psychology, University of Colorado, Muenzinger Bldg, Boulder, CO 80309-0345 (miklow@psych.colorado.edu).

Author Contributions: Dr Miklowitz verifies that he had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Financial Disclosure: Dr Nierenberg has been a consultant to Bristol-Myers Squibb, Genaissance, GlaxoSmithKline, Innpharma, Janssen, Eli Lilly, Novartis, Pfizer, Sepracor, Shire, Somerset, and Sumitomo; has received grant support from Bristol-Myers Squibb, Cedexoth, Cyberonics, Forest, GlaxoSmithKline, Janssen, Lichtwer, Eli Lilly, Pfizer, and Wyeth; and has received honoraria from Bristol-Myers Squibb, Cyberonics, Forest, GlaxoSmithKline, Eli Lilly, and Wyeth.

Funding/Support: The STEP-BD was funded in part by contract N01MH80001 from the National Institute of Mental Health (Dr Sachs). Support for the development of the psychosocial treatments was provided by grants MH29618 (Dr Frank), MH43931 (Dr Miklowitz), and MH55101 (Dr Miklowitz) from the National Institute of Mental Health and by the National Alliance for Research on Schizophrenia and Depression (Dr Miklowitz).

Disclaimer: Any opinions, findings, and conclusions or recommendations expressed in this publication are those of the authors and do not necessarily reflect the views of the National Institute of Mental Health. This article was approved by the Publication Committee of the STEP-BD.

Acknowledgment: We thank Debra Frankel, LCSW, for her supervision and coding of the IPSRT sessions.

REFERENCES

7. Kupper DJ, Frank E, Grochocinski VJ, Luther JF, Houck PR, Swartz HA, Mallinger...
18. Fristad MA, Gavazzi SM, Mackinaw-Koons B. Family psychoeducation: an ad-
120. Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, Tor-
16. Clarkin JF, Glick ID, Haas GL, Spencer JH, Lewis AB, Peyser J, Demane N, Good-
23. Miklowitz DJ. A review of evidence-based psychosocial interventions for bipolar
11. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related thera-
8. Tohen M, Suppes T, Baker RW, Risser RC, Evans AR, Calabrese JR. Olanzapine
7. Sackeim HA, Tohen M, Hyman S, Towse G, Reynolds C, Roy-Byrne P. A compara-
6. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
5. Montgomery SA, Asberg M. A depression scale designed to be sensitive to
4. Montgomery SA, Asberg M. A depression scale designed to be sensitive to
3. Montgomery SA, Asberg M. A depression scale designed to be sensitive to
2. Montgomery SA, Asberg M. A depression scale designed to be sensitive to
1. Montgomery SA, Asberg M. A depression scale designed to be sensitive to
38. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.
36. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
35. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
34. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
33. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
32. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
31. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
30. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
29. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
28. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
24. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
22. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
21. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
18. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
14. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
13. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
10. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
9. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
8. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
7. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
6. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
5. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
4. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
3. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
2. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
38. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
37. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
36. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
35. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
34. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
33. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
32. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
31. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
30. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
29. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
28. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
24. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
22. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
21. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
18. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
14. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
13. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
10. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
9. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
8. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
7. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
6. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
5. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
4. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
3. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
2. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to